Publicacións nas que colabora con Agustín Albillos Martínez (21)

2024

  1. Effectiveness and safety of azathioprine for inflammatory pouch disorders: results from the RESERVO study of GETECCU

    Therapeutic Advances in Gastroenterology, Vol. 17

  2. Longitudinal outcomes of obeticholic acid therapy in ursodiol-nonresponsive primary biliary cholangitis: Stratifying the impact of add-on fibrates in real-world practice

    Alimentary Pharmacology and Therapeutics, Vol. 59, Núm. 12, pp. 1604-1615

  3. The biochemical pattern defines MASLD phenotypes linked to distinct histology and prognosis

    Journal of Gastroenterology, Vol. 59, Núm. 7, pp. 586-597

  4. Types, behaviour and therapeutic requirements of inflammatory pouch disorders: Results from the RESERVO study of GETECCU

    Digestive and Liver Disease

2023

  1. Oportunistic diagnosis based on age and hepatitis C virus clearance: an essential step to improve the overall health of the liver

    Revista Espanola de Enfermedades Digestivas, Vol. 115, Núm. 3, pp. 128-132

  2. Tenofovir Disoproxil Fumarate Reduces the Severity of COVID-19 in Patients with Chronic Hepatitis B

    Digestive Diseases and Sciences, Vol. 68, Núm. 6, pp. 2731-2737

  3. Training and competence in Digestive Endoscopy: Statement Position Paper from the Spanish Society of Digestive Diseases

    Revista Espanola de Enfermedades Digestivas

2022

  1. Global multi-stakeholder endorsement of the MAFLD definition

    The Lancet Gastroenterology and Hepatology

2021

  1. Obeticholic Acid and Fibrates in Primary Biliary Cholangitis: Comparative Effects in a Multicentric Observational Study

    American Journal of Gastroenterology, Vol. 116, Núm. 11, pp. 2250-2257

2020

  1. Deep-sequencing reveals broad subtype-specific HCV resistance mutations associated with treatment failure

    Antiviral Research, Vol. 174

  2. Development and Validation of Hepamet Fibrosis Scoring System–A Simple, Noninvasive Test to Identify Patients With Nonalcoholic Fatty Liver Disease With Advanced Fibrosis

    Clinical Gastroenterology and Hepatology, Vol. 18, Núm. 1, pp. 216-225.e5

  3. Erratum to: “Significant fibrosis predicts new-onset diabetes mellitus and arterial hypertension in patients with NASH (J Hepatol 2020; 73: 17–25) (Journal of Hepatology (2020) 73(1) (17–25), (S0168827820301276), (10.1016/j.jhep.2020.02.028))

    Journal of Hepatology

  4. Significant fibrosis predicts new-onset diabetes mellitus and arterial hypertension in patients with NASH

    Journal of Hepatology, Vol. 73, Núm. 1, pp. 17-25

2019

  1. Elimination of hepatitis C. Positioning document of the Spanish Association for the Study of the Liver (AEEH)

    Gastroenterologia y Hepatologia, Vol. 42, Núm. 9, pp. 579-592

2018

  1. The effects of metabolic status on non-alcoholic fatty liver disease-related outcomes, beyond the presence of obesity

    Alimentary Pharmacology and Therapeutics, Vol. 48, Núm. 11-12, pp. 1260-1270

2017

  1. Effectiveness, safety and clinical outcomes of direct-acting antiviral therapy in HCV genotype 1 infection: Results from a Spanish real-world cohort

    Journal of Hepatology, Vol. 66, Núm. 6, pp. 1138-1148

  2. Treatment of hepatitis C virus infection in patients with cirrhosis and predictive value of model for end-stage liver disease: Analysis of data from the Hepa-C registry

    Hepatology, Vol. 65, Núm. 6, pp. 1810-1822

2016

  1. Addition of Simvastatin to Standard Therapy for the Prevention of Variceal Rebleeding Does Not Reduce Rebleeding but Increases Survival in Patients with Cirrhosis

    Gastroenterology, Vol. 150, Núm. 5, pp. 1160-1170.e3

2014

  1. Terapia triple en pacientes con fibrosis avanzada y cirróticos: Aspectos relevantes en la práctica clínica

    Gastroenterologia y Hepatologia, Vol. 37, Núm. S1, pp. 13-22

2009

  1. Simvastatin Lowers Portal Pressure in Patients With Cirrhosis and Portal Hypertension: A Randomized Controlled Trial

    Gastroenterology, Vol. 136, Núm. 5, pp. 1651-1658